Meet Butterworth Labs at Biotech Outsourcing Strategies Event
Butterworth Labs will be attending Biotech Outsourcing Strategies at the Congress Center in Basel, Switzerland.
Butterworth Labs will be attending Biotech Outsourcing Strategies at the Congress Center in Basel, Switzerland.
Live Webcast on Thursday, July 12, 2018 at 9am EDT | 2pm BST | 3pm CEST
A new report by Persistence Market Research titled “IV Tubing Sets and Accessories Market: Global Industry Analysis (2012–2016) and Forecast (2017 – 2025)” tracks the growth and performance of the global IV tubing sets and accessories market for a period of eight years from 2017 to 2025. According to this report, the global IV tubing sets and accessories market is projected to register a CAGR of 3.7% in terms of value during the projected period of 2017-2025 and be valued at US$ 1,248 Mn by the end of 2025. This growth is primarily driven by an enhanced sales network and distribution channels along with a wide availability of IV tubing sets.
Integration of smart technologies in pills has instrumented a ground-breaking transformation in the global healthcare marketplace. Initially, consumers and patients were diffident towards invasive surgical procedures and drug administration, albeit, their perspectives have undergone changes. There is a growing uptake for indigestible medical devices, which has propelled the consumption of smart pills. Elements such as cameras, trackers and sensors are being integrated in smart pills, making them a key tool to assess the health of consumer from within the body.
Technical experts representing Vertellus’ active product ingredient (API) technologies and contract manufacturing services will be at Chemspec Europe.
Several factors impacting the growth of the schizophrenia treatment market has been covered in an extensive research report titled “Schizophrenia Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2027)”. Persistence Market Research has presented all the facets of the market in a systematic manner outlining various opportunities, trends, key developments, key market players and growth influencing aspects. The research report presents a forecast analysis for a period of 10 years, starting from 2017 till 2027 along with historical data.
Technological innovations have revolutionized lifestyle, communication, business, travel, and healthcare. The healthcare technology industry is continually improving ways to treat neural-related medical conditions, coupled with a significant understanding of subsequent ramifications and consequences. On the other hand, the pharmaceutical landscape has also transitioned and opened itself to explore novel scientific approaches and innovative technologies within its core therapeutic areas.
NSF have added two new eLearning sessions to its online portal. NSF’s new pharma biotech eLearning includes short, targeted, highly focused “how to” sessions on common industry themes as well as introductions and overviews on topics essential for those new to the industry. Learn from NSF’s trusted industry experts and take away tools and techniques that can be used instantly in the workplace.
The ophthalmology sector has gained massive traction during the course of the last few years. This is a result of growing prevalence of diseases like macular edema, which is a severe case of swelling in the retina possibly leading to blindness. Looking at the significant increase in the number of macular edema cases, many new drugs have been introduced in the global market and several are still in the pipeline. Anti-VEGF and corticosteroid therapies are considered to be the standard therapies for prevention of vision loss in patients in various indications of macular edema. The other drug types that are part of the macular edema treatment market are immunosuppressant and biologics, and many new treatment types are expected to be introduced as the market continues to grow. The outcomes of a recent market research by Persistence Market Research has revealed the growth of the global non-infectious macular edema treatment market at a CAGR of 7.0% during the forecast period 2018-2026. The study also projects the market to reach a valuation of over US$ 17,200 Mn by the end of 2026.
As part of Pfanstiehl’s continual commitment to producing high-purity, low-endotoxin and low-metal (HPLE-LM) offerings for bioprocessing components, two new D-Galactose products were launched.